Understanding Treatment for Advanced EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)

Understanding Treatment for Late-Stage EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)

This podcast is for people who have late-stage EGFR-mutated non-small cell lung cancer, or anyone who wants to learn more about testing and treatment for it. The goal of this patient education activity is to help people who are living with late-stage EGFR-mutated non-small cell lung cancer and their care partners understand treatment plans for it.

You will learn about:

What late-stage EGFR-mutated non-small cell lung cancer is
How to keep track with your doctor of whether it is progressing
Different treatments for it and how to manage side effects

Certain treatments mentioned may not be approved by the US Food and Drug Administration (FDA) for EGFR-mutated non-small cell lung cancer but are recommended by the National Comprehensive Cancer Network (NCCN).

Join Danielle from GO2 as she talks to Dr. Joshua Sabari and Larry Gershon about early-stage EGFR-mutated non-small cell lung cancer and treatment plans.

LISTEN FROM YOUR APP: Apple Podcasts

Authors and Disclosures

Host

Danielle Hicks

Chief Patient OfficerGO2 Foundation for Lung CancerSan Carlos, California Danielle Hicks, has the following relevant financial relationships:Consultant or advisor for: Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Merck

Panelists

Joshua K. Sabari, MD

Attending PhysicianThoracic Medical OncologyAssistant Professor of MedicineNew York University Langone Health Perlmutter Cancer CenterNew York, New York Joshua K. Sabari, MD, has the following relevant financial relationships:Consultant or advisor for: AbbVie Inc.; AstraZeneca Pharmaceuticals LP; Bristol Myers Squibb Company; Genentech; Janssen; Jazz Pharmaceuticals, Inc.; Lilly; Loxo Oncology; Mirati; Navire; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Revolution Medicines; Sanofi Genzyme; TakedaResearch funding from: Janssen; Lilly; Loxo Oncology; Mirati; Regeneron Pharmaceuticals, Inc.

Larry Gershon

Patient AdvocatePalo Alto, California Larry Gershon, has the following relevant financial relationships:Consultant or advisor for: Boehringer Ingelheim Pharmaceuticals, Inc.

Editor

Ashwin Prasanna

Learning Designer, Medscape, LLC. Ashwin, Prasanna, has no relevant financial relationships.